| Discovery Laboratories, Inc. (DSCO:NASDAQ)
is a bio-pharmaceutical company whose mission is to develop
and commercialize medically novel therapeutics for critical
care. |
|
Approximate Employees: 36
FYE 12/31
|
2001
|
2000
|
1999
|
1998
|
|
Net Revenues ($000)
|
1,112
|
741
|
334
|
421
|
|
Net Income ($000)
|
(11,146)
|
(10,861)
|
(4,958)
|
(15,645)
|
|
Shareholders Equity ($000)
|
17,623
|
16,436
|
3,108
|
4,052
|
|
Shareholders Equity/Share
|
0.80
|
0.87
|
0.41
|
1.04
|
|
Earnings per share
|
(0.51)
|
(0.58)
|
(0.66)
|
(4.02)
|
|
Shares Outstanding (000)
|
22,038
|
18,806
|
7,545
|
3,896
|
|
Company reported for the second quarter
ended 6/30/02 a net loss of $(4,287,000) or $(0.16) per share
on revenues of $783,000 vs. a net loss of $(2,355,000) or
$(0.11) per share on revenues of $262,000 for the same period
last year.
Company reported for the six months ended
6/30/02 a net loss of $(7,657,000) or $(0.29) per share on
revenues of $1,020,000 vs. a net loss of $(4,415,000) or $(0.21)
per share on revenues of $718,000 for the same period last
year.
|
COMPANY CONTACT: Evan
Myrianthopoulos, Vice President of Finance;
(212) 564-3639 or (215) 340-4699
ext. 113 |
|
|
